SuperworthTeva Pharmaceutical Industries profit margin TEVA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- 4.1%
- Operating margin, 12 months
- 9.3%
- Net margin on a year earlier
- +5.0 pts
- Peer median
- 10.7%
Over the twelve months to Jun 30, 2026, Teva Pharmaceutical Industries kept 4.1% of its revenue as net profit, with an operating margin of 9.3% and a gross margin of 52.5%.
Five years earlier its net margin was −24.0%.
The median for 10 healthcare stocks of a similar size is 10.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 8.2% | 12.5% | 51.8% |
| FY2024 | −9.9% | −1.8% | 48.7% |
| FY2023 | −3.5% | 2.7% | 48.2% |
| FY2022 | −15.8% | −14.1% | 46.7% |
| FY2021 | 2.6% | 10.8% | 47.8% |
| FY2020 | −24.0% | −21.4% | 46.4% |
| FY2019 | −5.9% | −2.6% | 44.6% |
| FY2018 | −11.8% | −9.0% | 45.4% |
| FY2017 | −72.7% | −78.1% | 47.4% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 4.1% | +5.0 pts | 9.3% | |
| Q1 FY26 | 9.0% | +16.8 pts | 13.2% | |
| Q4 FY25 | 8.2% | +18.1 pts | 12.5% | |
| Q3 FY25 | 4.2% | +10.0 pts | 10.9% | |
| Q2 FY25 | −1.0% | +1.8 pts | 5.4% | |
| Q1 FY25 | −7.7% | −4.7 pts | 2.6% | |
| Q4 FY24 | −9.9% | −6.4 pts | −1.8% | |
| Q3 FY24 | −5.7% | +9.0 pts | 2.9% | |
| Q2 FY24 | −2.8% | +12.2 pts | 5.4% | |
| Q1 FY24 | −3.0% | +7.8 pts | 1.4% | |
| Q4 FY23 | −3.5% | +12.2 pts | 2.7% | |
| Q3 FY23 | −14.7% | −6.2 pts | −7.7% |
Against its peers
Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.
| Company | Profit margin |
|---|---|
| TEVATeva Pharmaceutical Industries | 4.1% |
| IQVIQVIA | 8.1% |
| MDLNMedline | n/m |
| WATWaters | 3.6% |
| IDXXIDEXX Laboratories | 25.0% |
| AAgilent Technologies | 19.5% |
| ONCBeOne Medicines | 10.7% |
| HUMHumana | 0.9% |
| EWEdwards Lifesciences | 15.4% |
| ILMNIllumina | 18.4% |
| BDXBecton, Dickinson and | 4.5% |
| Peer median | 10.7% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Teva Pharmaceutical Industries
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.